Drugs / BPZE1
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02453048 | Sep 2015 → Mar 2017 | pertussis | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 1 | NCT01188512 | Aug 2010 → Jun 2011 | pertussis | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT05461131 | Jun 2022 → Jul 2023 | pertussis | ILiAD Biotechnologies | Completed | Missed primary |
| Phase 2 | NCT05116241 | Nov 2021 → May 2024 | pertussis | ILiAD Biotechnologies | Completed | No outcome recorded |
| Phase 2 | NCT03942406 | Jun 2019 → Feb 2020 | pertussis | ILiAD Biotechnologies | Completed | No outcome recorded |
| Phase 2 | NCT03541499 | Oct 2018 → May 2020 | pertussis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPZE1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02453048 ↗ |
| Modality | Vaccine | “live attenuated nasal pertussis vaccine” PMID 24421886 ↗ Jan 2014 |
| Route | Intranasal | “given intranasally” PMID 24421886 ↗ Jan 2014 |